Ophirex was founded by Jerry Harrison, Matthew Lewin, Matthew R. Lewin.

How much funding has Ophirex raised?

Ophirex has disclosed $16.5M raised across 1 of its 2 known rounds.

Where is Ophirex headquartered?

Ophirex is headquartered in Corte Madera, US.

Ophirex

Corte Madera, US · Delaware corporation

Ophirex is a biotech company developing varespladib, an investigational oral capsule intended to treat snakebite envenomation by inactivating a key venom toxin found in most snake species. The drug is designed as a portable, field-administered rescue treatment to bridge the gap before hospital antivenom.

Biotech Deep Tech Healthtech

Founders & leadership

Jerry HarrisonCo-founder

Matthew LewinCo-founder

Matthew R. LewinCo-founder (former CEO, President, Chief Medical Officer & Chief Scientific Officer)

Jeremy GowlerExecutive / Director

Howard PienNamed on SEC filing

Nancy J. KochNamed on SEC filing

Sara CarterExecutive

Timothy Platts-MillsExecutive

DotsonFinance leader (Controller/Finance)

Reported raises · per SEC filings

Form D private placements

$16.5M disclosed across 1 of 2 rounds · 2019–2022

▶$16.5MraisedMar 2022 · 18 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Jeremiah HarrisonDirector
Derrick RossiDirector
Curt LaBelleDirector
Hans BishopDirector
Timothy GarnettDirector
Nancy J. KochExecutive Officer, Director
Matthew R. LewinDirector

Offering amount: $35M
Amount sold: $16.5M
First sale: Mar 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$5MofferedMar 2019 · Other

Rule 506(b)

Officers, directors & promoters on the filing

Jerry HarrisonDirector, Promoter
Matthew LewinExecutive Officer, Director, Promoter
Howard PienDirector, Promoter
Nancy J. KochExecutive Officer, Director, Promoter

Offering amount: $5M
Minimum investment: $5K
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Medscape88 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.

Gavi63 shared keywordsGavi, the Vaccine Alliance is a public-private partnership that funds and supports immunisation programmes to vaccinate children against infectious diseases in lower-income countries. It supports vaccines against 20 diseases and strengthens health and immunisation systems across 78 partner countries.

Companies competing with Ophirex for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
Department of DefenseDefense Health Program	Phase II	2023	$1.3M
Department of DefenseDefense Health Program	Phase II	2021	$1.5M
Department of DefenseDefense Health Program	Phase I	2018	$148.5K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Ophirex do?: Ophirex is a biotech company developing varespladib, an investigational oral capsule intended to treat snakebite envenomation by inactivating a key venom toxin found in most snake species. The drug is designed as a portable, field-administered rescue treatment to bridge the gap before hospital antivenom.
Who founded Ophirex?: Ophirex was founded by Jerry Harrison, Matthew Lewin, Matthew R. Lewin.
How much funding has Ophirex raised?: Ophirex has disclosed $16.5M raised across 1 of its 2 known rounds.
Where is Ophirex headquartered?: Ophirex is headquartered in Corte Madera, US.